Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Gatifloxacin

Gatifloxacin: A Powerful Fluoroquinolone for Bacterial Infections

Introduction

In the ongoing battle against bacterial infections, fluoroquinolones have played a significant role in modern medicine. Among them, gatifloxacin has emerged as a potent antibacterial agent, known for its broad-spectrum activity, excellent tissue penetration, and multiple formulations. Whether used systemically or topically, gatifloxacin has earned its place in treating various infections, particularly those involving the respiratory tract, eyes, and urinary system.

Gatifloxacin

Gatifloxacin is a fourth-generation fluoroquinolone antibiotic. Like other quinolones, it works by inhibiting bacterial DNA replication, but gatifloxacin stands out due to its enhanced activity against Gram-positive bacteria—especially Streptococcus pneumoniae—while retaining potent Gram-negative coverage.Initially approved for systemic use, gatifloxacin is now more commonly used in ophthalmology, especially in the treatment of bacterial conjunctivitis and post-operative infections.

Mechanism of Action

Gatifloxacin exerts its bactericidal action by inhibiting two key bacterial enzymes involved in DNA processes:

  1. DNA Gyrase (Topoisomerase II) – Prevents DNA supercoiling

  2. Topoisomerase IV – Inhibits separation of daughter chromosomes after replication

These enzymes are essential for bacterial DNA replication, transcription, and repair. Blocking them leads to bacterial cell death, making gatifloxacin a bactericidal agent.

What makes gatifloxacin a fourth-generation fluoroquinolone is its enhanced activity against Gram-positive cocci, especially multidrug-resistant strains like penicillin-resistant Streptococcus pneumoniae (PRSP).

Pharmacokinetics

Oral Form

  • Absorption: Rapid and well absorbed (~96% bioavailability)

  • Peak Plasma Levels: Achieved in 1–2 hours

  • Half-life: Approximately 7–14 hours

  • Excretion: Mainly through kidneys (unchanged drug)

  • Tissue Penetration: Excellent, including lungs, prostate, and ocular tissues

Ophthalmic Form

  • Delivers high local concentrations to eye tissues

  • Minimal systemic absorption, reducing risk of systemic side effects

Clinical Uses

Systemic Use (Now Withdrawn in Some Regions)

Historically, gatifloxacin tablets and IV formulations were used for:

  • Community-acquired pneumonia (CAP)

  • Acute bacterial sinusitis

  • Chronic bronchitis exacerbations

  • Urinary tract infections (UTIs)

  • Skin and soft tissue infections

However, due to concerns over dysglycemia (glucose abnormalities), systemic use has been withdrawn in some countries like the U.S. and Canada.

Ophthalmic Use (Currently in Use)

Still widely available and used for:

  • Bacterial conjunctivitis

  • Blepharitis

  • Prophylaxis after eye surgeries (e.g., cataract removal, LASIK)

  • Corneal ulcers (off-label)

Common brand names include:

  • Zymaxid® (U.S.)

  • Gatilox®, Gatiflo®, Gatiforce® (India and other regions)

Spectrum of Activity

Gram-positive Bacteria:

  • Streptococcus pneumoniae

  • Staphylococcus aureus (including MSSA)

  • Streptococcus pyogenes

Gram-negative Bacteria:

  • Haemophilus influenzae

  • Moraxella catarrhalis

  • Neisseria gonorrhoeae

  • E. coli (variable susceptibility due to resistance)

Atypical Pathogens:

  • Mycoplasma pneumoniae

  • Chlamydophila pneumoniae

  • Legionella pneumophila

Anaerobes:

  • Limited activity, not recommended as monotherapy for anaerobic infections

Gatifloxacin is not effective against Pseudomonas aeruginosa, making it less useful in infections like cystic fibrosis-related lung disease.

Formulations Available

Formulation Brand Names Use
Eye drops (0.3%, 0.5%) Zymaxid, Gatilox Bacterial eye infections
Oral tablets (Discontinued in some regions) Tequin (withdrawn) Respiratory/urinary infections
Intravenous solution (Discontinued in most markets) Tequin IV Severe infections

Most commonly, gatifloxacin is used in ophthalmic preparations due to its excellent local action and low side effect profile.

Dosage Guidelines

Ophthalmic:

  • Bacterial Conjunctivitis:

    • Days 1–2: 1 drop every 2 hours while awake (up to 8 times/day)

    • Days 3–7: 1 drop 2–4 times/day

  • Surgical Prophylaxis:

    • 1 drop 1 hour before surgery, then as directed postoperatively

Always follow physician instructions regarding duration and frequency.

Side Effects

Systemic Form (Now Discontinued):

  • Hypoglycemia or hyperglycemia

  • Nausea, dizziness

  • QT prolongation

  • Photosensitivity

  • CNS effects (headache, confusion, seizures)

These issues led to the withdrawal of oral and IV formulations in many countries.

Ophthalmic Form:

  • Mild burning or stinging

  • Eye irritation or redness

  • Blurred vision temporarily after instillation

  • Rare allergic reactions

Compared to systemic forms, the topical (ophthalmic) version is considered safe, even in children.

Resistance and Concerns

Like all antibiotics, misuse or overuse of gatifloxacin can lead to bacterial resistance. Mechanisms include:

  • Target site mutations in topoisomerase enzymes

  • Efflux pumps that eject the drug from the bacterial cell

  • Plasmid-mediated resistance via qnr genes

To mitigate this, it's crucial to:

  • Use gatifloxacin only when bacterial infection is confirmed or strongly suspected

  • Avoid prolonged or repeated use without medical supervision

  • Rotate antibiotics when treating recurrent infections

Drug Interactions

For systemic gatifloxacin (where still used), interactions include:

  • Antidiabetic medications: May cause unpredictable blood sugar swings

  • QT-prolonging drugs: Additive risk for arrhythmias

  • Antacids, calcium, magnesium: Reduce absorption of oral gatifloxacin

Topical formulations do not interact significantly with other drugs, making them a safe option even in polypharmacy settings.

Special Populations

Pregnancy and Lactation

  • FDA Pregnancy Category C (limited data)

  • Ophthalmic use may be considered safe due to minimal systemic absorption

Pediatric Use

  • Approved for bacterial conjunctivitis in children as young as 1 year

Elderly

  • Ophthalmic form is safe

  • Systemic form was associated with increased risk of blood glucose abnormalities in the elderly

Gatifloxacin vs. Other Fluoroquinolones

Feature Gatifloxacin Moxifloxacin Levofloxacin Ciprofloxacin
Generation 4th 4th 3rd 2nd
Gram+ Activity Strong Very strong Moderate Weak
Gram– Activity Strong Moderate Strong Very strong
Atypicals Good Excellent Good Moderate
Ophthalmic Use Yes Yes Yes Yes
Systemic Use Discontinued in many areas Available Available Widely used
Glycemic Side Effects Yes (significant) Minimal Minimal Rare

Gatifloxacin’s systemic toxicity limited its usage, but it remains a topical mainstay in eye care.

Research and Future Directions

1. Nanotechnology in Ophthalmic Delivery

New formulations using nanoemulsions and liposomes aim to improve ocular penetration and reduce dosing frequency.

2. Gatifloxacin Combinations

Research is exploring fixed-dose combinations of gatifloxacin with anti-inflammatory agents like dexamethasone or antifungals for broader ophthalmic coverage.

3. Resistance Surveillance

Global studies continue to monitor resistance trends in ocular pathogens like Staphylococcus epidermidis and S. aureus, which affect gatifloxacin’s efficacy.

Conclusion

Gatifloxacin represents both the promise and challenges of modern antibiotic therapy. While its systemic use has declined due to adverse effects, its ophthalmic formulation remains a cornerstone in treating bacterial eye infections, thanks to excellent efficacy, broad spectrum, and safety. Used judiciously and with proper medical oversight, gatifloxacin continues to offer reliable outcomes in targeted infections. As research advances and novel delivery systems emerge, gatifloxacin may find renewed applications beyond the eye clinic, always with an eye on balancing efficacy and safety.